Data provided by iNet BFA
Loading...
See More

Aspen unit to buy drug portfolio from GSK

Aug 15 2012 08:53

Company Data

ASPEN PHARMACARE HOLDINGS LIMITED [JSE:APN]

Last traded 314.10
Change 3.74
% Change 0.01
Cumulative volume 453757
Market cap 143.34bn

Last Updated: 02/09/2014 at 03:50. Prices are delayed by 15 minutes. Source: McGregor BFA

Related Articles

Drug firms win R2.5bn tender

Pfizer pulls false Centrum vitamin claims

Adcock buys Indian medicine business

Fake Grand-Pas pulled from shelves

Aspen buys GSK brands

Aspen prepared to help bridge ARV shortages

 
Johannesburg - Aspen Pharmacare [JSE:APN] said on Wednesday its subsidiary, Aspen Global, will pay £172m for GlaxoSmithKline's pharmaceutical products distributed in Australia.

Aspen said in a statement that the purchase price for the 25 pharmaceutical products was subject to a small reduction should the deal not be completed by October 31.

It said the deal will be funded from new offshore debt facilities and that Aspen Australia was expected to distribute the products.

The deal was subject to regulatory approvals from Australian authorities, the company said.

Aspen also announced in April that it would pay $263m for GSK's international over-the-counter brands.
 
aspen  |  glaxosmithkline  |  drugs
NEXT ON FIN24X

 
 
 

Read Fin24’s Comments Policy

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
0 comments
Add your comment
Comment 0 characters remaining
 

Company Snapshot

We're talking about:

Small Business

“Hippie sense makes business sense,” an entrepreneur said, adding that "purpose" was core to success.
 

Money Clinic

Money Clinic
Do you have a question about your finances? We'll get an expert opinion.
Click here...
Loading...